A
Amanda L. Christie
Researcher at Harvard University
Publications - 50
Citations - 7580
Amanda L. Christie is an academic researcher from Harvard University. The author has contributed to research in topics: Leukemia & Myeloid leukemia. The author has an hindex of 29, co-authored 49 publications receiving 6415 citations. Previous affiliations of Amanda L. Christie include AstraZeneca & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Elizabeth C. Townsend,Mark A. Murakami,Alexandra N. Christodoulou,Amanda L. Christie,Johannes Köster,Tiffany DeSouza,Elizabeth A. Morgan,Scott P. Kallgren,Huiyun Liu,Shuo-Chieh Wu,Olivia Plana,Joan Montero,Kristen E. Stevenson,Prakash Rao,Raga Vadhi,Michael Andreeff,Philippe Armand,Karen K. Ballen,Patrizia Barzaghi-Rinaudo,Sarah Cahill,Rachael A. Clark,Vesselina G. Cooke,Matthew S. Davids,Daniel J. DeAngelo,David M. Dorfman,Hilary Eaton,Benjamin L. Ebert,Julia Etchin,Brant Firestone,David C. Fisher,Arnold S. Freedman,Ilene Galinsky,Hui Gao,Jacqueline S. Garcia,Francine Garnache-Ottou,Timothy A. Graubert,Alejandro Gutierrez,Alejandro Gutierrez,Ensar Halilovic,Marian H. Harris,Zachary T. Herbert,Steven M. Horwitz,Giorgio Inghirami,Andrew M. Intlekofer,Moriko Ito,Shai Izraeli,Eric D. Jacobsen,Caron A. Jacobson,Sébastien Jeay,Irmela Jeremias,Michelle A. Kelliher,Raphael Koch,Marina Konopleva,Nadja Kopp,Steven M. Kornblau,Andrew L. Kung,Thomas S. Kupper,Nicole R. LeBoeuf,Ann S. LaCasce,Emma Lees,Loretta S. Li,A. Thomas Look,Masato Murakami,Markus Müschen,Donna Neuberg,Samuel Y. Ng,Oreofe O. Odejide,Stuart H. Orkin,Rachel R. Paquette,Andrew E. Place,Justine E. Roderick,Jeremy Ryan,Stephen E. Sallan,Brent Shoji,Lewis B. Silverman,Robert J. Soiffer,David P. Steensma,Kimberly Stegmaier,Richard Stone,Jerome Tamburini,Aaron R. Thorner,Paul Van Hummelen,Martha Wadleigh,Marion Wiesmann,Andrew P. Weng,Jens Wuerthner,David A. Williams,Bruce M. Wollison,Andrew A. Lane,Anthony Letai,Monica M. Bertagnolli,Jerome Ritz,Myles Brown,Henry W. Long,Jon C. Aster,Margaret A. Shipp,James D. Griffin,David M. Weinstock,David M. Weinstock +98 more
TL;DR: It is demonstrated that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease.
Journal ArticleDOI
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
Alex Kentsis,Casie Reed,Casie Reed,Kim L. Rice,Takaomi Sanda,Takaomi Sanda,Scott J. Rodig,Eleni Tholouli,Amanda L. Christie,Amanda L. Christie,Peter J. M. Valk,Ruud Delwel,Vu N. Ngo,Jeffery L. Kutok,Suzanne E. Dahlberg,Lisa A. Moreau,Lisa A. Moreau,Richard J. Byers,Richard J. Byers,James G. Christensen,George F. Vande Woude,Jonathan D. Licht,Andrew L. Kung,Andrew L. Kung,Louis M. Staudt,A. Thomas Look,A. Thomas Look +26 more
TL;DR: The results show a widespread dependence of AML cells on autocrine activation of MET, as well as the key role of compensatory upregulation of HGF expression in maintaining leukemogenic signaling by this receptor.
Journal ArticleDOI
Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming
Brian E. Schwartz,Matthias D. Hofer,Madeleine E. Lemieux,Daniel E. Bauer,Michael J. Cameron,Nathan West,Elin S. Agoston,Nicolas Reynoird,Saadi Khochbin,Tan A. Ince,Amanda L. Christie,Katherine A. Janeway,Sara O. Vargas,Antonio R. Perez-Atayde,Jon C. Aster,Stephen E. Sallan,Andrew L. Kung,James E. Bradner,Christopher A. French +18 more
TL;DR: Findings provide preclinical support for trials of HDACi in patients with NMC, and show that expression of BRD4-NUT is associated with globally decreased histone acetylation and transcriptional repression.
Journal ArticleDOI
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells
Julia Etchin,Qi Sun,Alex Kentsis,Alicia Farmer,Zi Chao Zhang,Takaomi Sanda,Marc R. Mansour,C. Barcelo,D. McCauley,M. Kauffman,S. Shacham,Amanda L. Christie,Andrew L. Kung,Scott J. Rodig,Yuh Min Chook,A T Look +15 more
TL;DR: KPT-SINE CRM1 antagonists represent a novel class of drugs that warrant further testing in AML patients and exhibit potent antileukemic activity, inducing apoptosis at nanomolar concentrations in a panel of 14 human acute myeloid leukemia cell lines representing different molecular subtypes of the disease.
Journal ArticleDOI
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
Julia Etchin,Takaomi Sanda,Takaomi Sanda,Marc R. Mansour,Marc R. Mansour,Alex Kentsis,Alex Kentsis,Joan Montero,Bonnie Thi Le,Bonnie Thi Le,Amanda L. Christie,Amanda L. Christie,Dilara McCauley,Scott J. Rodig,Scott J. Rodig,Michael Kauffman,Sharon Shacham,Richard Stone,Anthony Letai,Andrew L. Kung,Andrew L. Kung,A. Thomas Look,A. Thomas Look +22 more
TL;DR: The results show that SINE CRM1 antagonists represent promising ‘first‐in‐class’ drugs with a novel mechanism of action and wide therapeutic index, and imply that drugs of this class show promise for the targeted therapy of T‐ALL and AML.